Yi-you J. Huang
Haikou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 20, 2026
Discovery of Novel MDH2 Inhibitor 28i by Secondary Development of Glibenclamide with Potent Antiaging Activities.
Journal: Journal of medicinal chemistry
Published: January 23, 2026
Structure-Based Optimization of Imidazopyridine Derivatives as Selective and Orally Bioavailable Phosphodiesterase 10A Inhibitors with Reduced Blood-Brain Barrier Penetration for the Treatment of Idiopathic Pulmonary Fibrosis.
Journal: Journal of medicinal chemistry
Published: November 21, 2025
Discovery of pinoresinol dimethyl ether as a natural PDE4 inhibitor with anti-psoriatic effects.
Journal: Bioorganic chemistry
Published: November 10, 2025
Discovery of novel 2,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one derivatives as PDE2 inhibitors with Alzheimer's disease therapeutic potential.
Journal: European journal of medicinal chemistry
Published: September 09, 2025
Structure-Based Optimization of Moracin M as Potent and Selective PDE4 Inhibitors with Antipsoriasis Effects.
Journal: Journal of medicinal chemistry
Published: March 11, 2025
A novel phosphodiesterase 4/5 dual-target inhibitor ameliorates neuroinflammation via the NF-κB and JNK pathway.
Journal: International journal of biological macromolecules
Published: February 19, 2025
Discovery of novel azetidine-based imidazopyridines as selective and orally bioavailable inhibitors of phosphodiesterase 10A for the treatment of pulmonary arterial hypertension.
Journal: European journal of medicinal chemistry
Published: January 08, 2025
Inhalable Carbonyl Sulfide Donor-Hybridized Selective Phosphodiesterase 10A Inhibitor for Treating Idiopathic Pulmonary Fibrosis by Inhibiting Tumor Growth Factor-β Signaling and Activating the cAMP/Protein Kinase A/cAMP Response Element-Binding Protein (CREB)/p53 Axis.
Journal: ACS pharmacology & translational science
Published: November 15, 2024
Glibenclamide targets MDH2 to relieve aging phenotypes through metabolism-regulated epigenetic modification.
Journal: Signal transduction and targeted therapy
Published: August 23, 2024
Discovery and optimization of 4-(imidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine derivatives as novel phosphodiesterase 4 inhibitors.
Journal: Molecular diversity
Published: August 03, 2024
Last Updated: 09/26/2026